Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It treats myasthenia gravis by increasing muscle strength in affected patients.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon (pyridostigmine bromide) is used to manage disorders of the neuromuscular junction, primarily myasthenia gravis.

Myasthenia gravis: improves muscle strength and reduces fatigue in patients with this autoimmune condition. Reversal of neuromuscular blockade: facilitates recovery of normal muscle function after surgery when non‑depolarizing relaxants have been used. Prophylaxis against nerve‑agent exposure: provides temporary protection for individuals at risk of certain chemical warfare agents.

Pyridostigmine bromide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Abdominal cramps - Increased salivation - Muscle cramps - Sweating

Serious or Rare Side Effects: - Bradycardia or other cardiac rhythm disturbances - Bronchospasm or severe respiratory difficulty - Anaphylactic or severe allergic reactions - Cholinergic crisis with muscle weakness and respiratory failure - Seizures or convulsions

Use of Mestinon requires careful monitoring and specific safety measures.

Monitor for cholinergic excess: watch for signs such as muscle twitching, sweating, or diarrhea. Adjust dose in renal impairment: reduced clearance may increase drug levels. Caution in asthma or COPD: anticholinergic effects can exacerbate bronchospasm. Avoid concurrent anticholinergic agents: may diminish therapeutic effect. Review cardiac status in patients with bradyarrhythmias: pyridostigmine can lower heart rate. Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Pyridostigmine bromide can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin): may potentiate neuromuscular blockade. - Non‑depolarizing muscle relaxants (e.g., vecuronium): increase risk of prolonged paralysis. - Strong anticholinergic drugs (e.g., atropine): reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia. - Diuretics (e.g., furosemide): can affect electrolyte balance, influencing drug response. - Cardiac glycosides (e.g., digoxin): monitor for additive vagal effects.